Senomyx Inc

Senomyx — Proxy Contest (April 2017)

31 slides from Senomyx's proxy contest presentation, Apr 21, 2017

  1. Slide 1: Concerned Shareholders and Nominees of Senomyx Investor Presentation

    CONCERNED SHAREHOLDERS AND NOMINEES OF SENOMYX April, 2017 Investor Presentation

  2. Slide 2: Table of contents

    Table of contents • Who We Are • Long History of Underperformance by Incumbent Board • Our Nominees and their Expertise • Going Forward

  3. Slide 3: Who We Are

    Who We Are • Nominees with long history of public company turnaround experience • Committed to unlocking shareholder value

  4. Slide 4: Underperformance

    Underperformance 0 50 100 150 200 250 300 350 2011 2012 2013 2014 2015 2016 Senomyx, Inc. NASDAQ Composite NASDAQ Biotechnology Name 2011 2012 2013 2014 2015 2016 Senomyx , Inc. 100 48.3 145.4 172.7 108.3 27.6 NASDAQ Composite 100 116.4 165.5 188.7 200.3 216.5 NASDAQ Biotechnology 100 134.7 232.4 30

  5. Slide 5: Senomyx vs peer group average, one year

    1 Year Chart 0.0 50.0 100.0 150.0 200.0 250.0 1-Apr-16 1-May-16 1-Jun-16 1-Jul-16 1-Aug-16 1-Sep-16 1-Oct-16 1-Nov-16 1-Dec-16 1-Jan-17 1-Feb-17 1-Mar-17 1-Apr-17 Senomyx Inc Peer group average

  6. Slide 6: Senomyx vs peer group average, three years

    3 Year Chart 0.0 20.0 40.0 60.0 80.0 100.0 120.0 140.0 160.0 180.0 1-May-14 1-Jun-14 1-Jul-14 1-Aug-14 1-Sep-14 1-Oct-14 1-Nov-14 1-Dec-14 1-Jan-15 1-Feb-15 1-Mar-15 1-Apr-15 1-May-15 1-Jun-15 1-Jul-15 1-Aug-15 1-Sep-15 1-Oct-15 1-Nov-15 1-Dec-15 1-Jan-16 1-Feb-16 1-Mar-16 1-Apr-16 1-May-16 1-Jun-16

  7. Slide 7: Senomyx vs peer group average, longer period

    5 Year Chart 0.0 100.0 200.0 300.0 400.0 500.0 600.0 Senomyx Inc Peer group average

  8. Slide 8: Senomyx Peer group chart

    Senomyx Peer group chart

  9. Slide 9: Peer group chart, one year

    1 Year Chart 0.0 100.0 200.0 300.0 400.0 500.0 600.0 1-Apr-16 1-May-16 1-Jun-16 1-Jul-16 1-Aug-16 1-Sep-16 1-Oct-16 1-Nov-16 1-Dec-16 1-Jan-17 1-Feb-17 1-Mar-17 1-Apr-17 Senomyx Inc Anika Therapeutics Inc ArQule, Inc Array Biopharma Inc Cytori Therapeutics Inc Codexis, Inc Dynavax Technologies Corp

  10. Slide 10: Peer group chart, three years

    3 Year Chart 0.0 100.0 200.0 300.0 400.0 500.0 600.0 700.0 1-May-14 1-Jun-14 1-Jul-14 1-Aug-14 1-Sep-14 1-Oct-14 1-Nov-14 1-Dec-14 1-Jan-15 1-Feb-15 1-Mar-15 1-Apr-15 1-May-15 1-Jun-15 1-Jul-15 1-Aug-15 1-Sep-15 1-Oct-15 1-Nov-15 1-Dec-15 1-Jan-16 1-Feb-16 1-Mar-16 1-Apr-16 1-May-16 1-Jun-16 1-Jul-1

  11. Slide 11: Peer group chart, five years

    5 Year Chart 0.0 200.0 400.0 600.0 800.0 1,000.0 1,200.0 1,400.0 Senomyx Inc Anika Therapeutics Inc ArQule, Inc Array Biopharma Inc Cytori Therapeutics Inc Dynavax Technologies Corp Exelixis, Inc Geron Corp Inovio Pharmaceuticals Inc Ligand Pharmaceuticals Inc Neurocrine Biosciences, Inc Orexigen Th

  12. Slide 12: Peer group chart, ten years

    10 Year Chart 0.0 50.0 100.0 150.0 200.0 250.0 300.0 350.0 400.0 450.0 500.0 1-May-07 1-May-08 1-May-09 1-May-10 1-May-11 1-May-12 1-May-13 1-May-14 1-May-15 1-May-16 Senomyx Inc Anika Therapeutics Inc ArQule, Inc Array Biopharma Inc Cytori Therapeutics Inc Dynavax Technologies Corp Exelixis, Inc Ge

  13. Slide 13: Our Nominees

    Our Nominees

  14. Slide 14: Barry A. Igdaloff

    Barry A. Igdaloff , age 62, has served on the Board of Directors at Novation Companies, Inc. since 2009. He is currently chairman of the Board and the audit committee. He has been the sole proprietor of Rose Capital, an investment advisor in Columbus, Ohio, since 1995. Mr. Igdaloff has been a direct

  15. Slide 15: Case study: Dynex Capital

    Case study: Dynex Capital • During his tenure, the Board lead a series of strategic initiatives including strategic sales of assets, sale of its delinquent property tax receivables portfolio, recapitalization of its equity capital structure and changed its strategy to invest significant portion of i

  16. Slide 16: Significant expertise

    Significant expertise ▪ Since he is an investor, Mr. Igdaloff brings “capital allocation” and “ownership mentality” to the companies that he serves. ▪ Skin in the game in the companies that he serves/served as a Director: - Novation Companies, Inc.: 8.5% (Chairman of the Board) - Dynex Capital, Inc.

  17. Slide 17: Lee Keddie

    Lee Keddie Lee Keddie is a Results - Driven Business Executive effective at leading fast - paced B2B manufacturing and product companies in both private and public sectors. He has a track record of delivering exceptional Revenue (18% CAGR) Earnings (40% CAGR) and Free Cash Flow growth (38 % CAGR) ov

  18. Slide 18: Case Study #1: Operational expertise, HKX

    Case Study #1 Operational expertise HKX Mr. Keddie spent 13 years with HKX, as a Co - owner, President & General Manager. • During his tenure, he transformed a hydraulic components startup from $1.8M revenue and 12 people, to a nationally recognized niche market leader with $18M Revenue, 55 employee

  19. Slide 19: Case study #2: Stephan Co.

    Case study #2: Stephen Co. 0 1 2 3 4 5 6 7 8 Jan-2003 Jan-2006 Jan-2009 Jan-2012 Jan-2015 Stock price performance of Stephan Co. before Mr. Keddie’s appointment as a director 0 0.5 1 1.5 2 2.5 Stock price performance of Stephan Co. after Mr. Keddie’s appointment as a director ▪ Stephan Company had a

  20. Slide 20: Benjamin E. Large

    Benjamin E. Large, age 38, is currently the Managing Partner at Nutmeg Investments LLC, an investment company (“Nutmeg”), and has worked there since January 2012. Nutmeg has a value oriented approach to investing and works directly with the companies it invests in. He has worked directly with multin

  21. Slide 21: Case Study: The Stephan Co.

    Case Study : The Stephan Co. The Stephan Company had at its core a highly profitable, industry - leading Barber Distribution business and excess low - basis real estate. Opportunity for Improvement The company was suffering from heavy losses in their stale brands business. Turnaround Approach Activi

  22. Slide 22: Gus D. Halas

    Mr. Gus D. Halas serves as a Partner of White Deer Energy. Mr. Halas served as the Chief Executive Officer and President of the Central Operating Companies of Central Garden & Pet Company (Central Garden & Pet Corp.) from April 18, 2011 to June 6, 2013. He served as the President and Chief Executive

  23. Slide 23: Case study #1: Operational turnaround

    Case study #1 Operational turnaround Throughout his career, Mr. Halas has successfully implemented turnaround initiatives at a number of companies. T - 3 Energy Services ▪ During his tenure, revenue grew 3 times to $218 million and operating profit increased by 4X. ▪ He successfully oversaw the inte

  24. Slide 24: Case study #2: Trusted and praised by investors

    “ Halas is effectively controlling the operations of the company and attempting to transform the company from the boondoggle described above into one integrated, multi - brand company that has improved processes, reduced number of facilities, fewer SKUs, and a centralized process for all divisions.”

  25. Slide 25: David W. Pointer

    David W. Pointer is the Managing Partner of V.I. Capital Management, LLC. Prior to V.I. Capital, David was a Sr. Portfolio Manager and Sr. Vice President at ICM Asset Management in Spokane, Washington; as well as Portfolio Manager at AIM/INVESCO Investments. David has served on numerous boards of di

  26. Slide 26: Significant achievements

    Significant achievements Portfolio management achievements • David has approximately 20 years of experience managing portfolios, assisting companies in developing strategic direction and increasing returns on capital, and offering merger and acquisition advice. • During his tenure as Portfolio Manag

  27. Slide 27: Robert G. Pearse

    Robert G. Pearse Robert G. Pearse, age 57, currently serves as a Managing Partner at Yucatan Rock Ventures where he specializes in technology investments and consulting since August 2012. Mr. Pearse serves as Chairman of the Board of directors for Crossroads Systems, Inc. (NASDAQ:CRDS) since May 201

  28. Slide 28: Mr. Pearse track record

    Mr. Pearse is a Silicon Valley veteran with a proven track record of identifying and growing technology firms, from startup to F500. • As Vice President of Strategy at NetApp, Inc., Mr. Pearse led the computer storage company from a mid - sized company to F500 listing during his 7 year tenure. • As

  29. Slide 29: Mark D. Stolper

    Mr . Mark D . Stolper has served as the Chief Financial Officer and Executive Vice President of RadNet , Inc . since July 2004 . Mr . Stolper was employed at Dillon Read Capital Management LLC . He worked at Dillon, Read & Co . Inc . Prior to joining RadNet , he has diverse experiences in investment

  30. Slide 30: Metropolitan Health Networks share price performance

    0 1 2 3 4 Dec-2006 Dec-2007 Dec-2008 Dec-2009 Share Price Performance of Metropolitan Health Networks Before Mr. Stolper’s appointment as a director 0 2 4 6 8 10 12 Apr-2010 Apr-2011 Apr-2012 Share Price Performance of Metropolitan Health Networks After Mr. Stolper’s appointment as a director ▪ In 2

  31. Slide 31: Next Steps

    Next Steps • The Concerned Shareholders and Nominees of Senomyx will seek all opportunities to maximize stockholder value through the careful evaluation of all components of the business. • Footnote: Steel Partners Holdings, Cannell Capital, LLC and Maglan Capital, LP as mentioned in Gus Halas’ bio

Senomyx — Proxy Contest (April 2017) on 6ix